Baird Financial Group
SANA icon

Baird Financial Group’s Sana Biotechnology SANA Stock Holding History

Baird Financial Group’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$41.6K – 1800
2024
Q3 		$41.6K Buy
+10,000
New +$52.5K ﹤0.01% 1729

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baird Financial Group's SANA Position: Q4 2024 in Review

Baird Financial Group sold out of Sana Biotechnology (SANA) in Q4 2024, closing a stake of 10,000 shares — an estimated $41.6K sold.

Baird Financial Group first reported a position in SANA in Q3 2024 and held it in 1 quarter. The position peaked at $41.6K in Q3 2024. 164 funds tracked by Wall St. Rank hold SANA as of Q4 2024.

  • Baird Financial Group reported no remaining Sana Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Baird Financial Group sold 10,000 Sana Biotechnology shares in Q4 2024, an estimated $41.6K.
  • Baird Financial Group first reported a position in Sana Biotechnology in Q3 2024 and held it in 1 quarter.
  • Baird Financial Group's Sana Biotechnology position peaked at $41.6K in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2024.

Based on Baird Financial Group's 13F filing for Q4 2024, filed 14 Feb 2025.